Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest reported Q2 2026 net loss of $5.2 million ($0.34 per share) and cash balance deteriorated to $0.8 million from $7.7 million at year-end, though operating cash burn of $10.4 million over six months was partially offset by $3.4 million in recent capital raises. The company announced positive interim results for TPST-2003 with 100% complete response rate across 15 CAR-T-naïve patients in ongoing Phase 1/2a trials, while executing a strategic partnership with Senlang Biotechnology to advance TPST-4003 with first patient dosing expected in Q4 2026. Board was strengthened with appointments of Drake Richey and Dr.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Drug Name
- TPST-4003, TPST-2003
- Revenue Yoy
- 0
- Deal Value Usd
- 0
- Phase Of Trial
- Phase 1/2a
- Offering Price
- 0
- Shares Offered
- 0
- Rd expenses q2 2026
- 1819000
- Cash balance q2 2026
- 779000
- Cash balance dec 2025
- 7707000
- Complete response rate
- 100%
- Private placement proceeds
- 1700000
- Warrant inducement proceeds
- 2000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.